Australia’s trusted immunisation experts
19 November 2026 | NewsUS loses measles elimination status – what does this mean for Australia?Read the full article
Coversheet on evidence assessment for the use of 20vPCV in children
Comparison of 20vPCV with 13vPCV+23vPPV in Aboriginal and Torres Strait Islander infants and infants and children with a risk condition in a 3+1 schedule
Comparison of 20vPCV with 13vPCV in non-Indigenous infants without a risk condition in a 2+1 schedule
Coversheet on evidence assessment by ATAGI using the GRADE framework for the use of 21vPCV in adults
Comparison of 21vPCV (V116) with 15vPCV+23vPPV in adults aged ≥18 years with risk conditions
Comparison of 21vPCV (V116) to 15vPCV+23vPPV in Aboriginal and Torres Island peoples aged ≥50 years without risk conditions
Comparison of 21vPCV (V116) with 20vPCV in non-Indigenous adults aged ≥70 years without risk conditions
Coversheet on evidence assessment by ATAGI using the GRADE framework for 20vPCV in adults
Use of 20vPCV versus 13vPCV in adults aged >70 years without specific risk conditions
Use of 20vPCV versus 13vPCV + 23vPPV in adults aged >18 years with specific risk conditions
Use of 20vPCV versus 13vPCV in First Nations adults aged >50 years without specific risk conditions
Compared to 13vPCV in adults aged >70 years without specific risk conditions
Compared to 13vPCV+23vPPV in adults aged >18 years with specific risk conditions
Compared to 13vPCV+23vPPV in First Nations adults aged >50 years without specific risk conditions
Coversheet on evidence assessment by ATAGI using the GRADE framework for 15vPCV in adults
Use of 15vPCV versus 13vPCV in adults aged ≥70 years without specific risk factors
Use of 15vPCV + 23vPPV versus 13vPCV + 23vPPV in Indigenous adults aged ≥50 years without specific risk factors
Use of 15vPCV + 23vPPV versus 13vPCV + 23vPPV in adults aged ≥18 years with specific risk factors
Compared to 13-valent pneumococcal vaccine (13vPCV) in adults aged ≥70 years without specific risk factors
Compared to 13vPCV + 23-valent pneumococcal polysaccharide vaccine (23vPPV) in Indigenous adults aged ≥50 years without specific risk factors
Compared to 13vPCV + 23vPPV in adults aged ≥18 years with specific risk factors
Note: These GRADE documents should be read as a supplement to Australian Immunisation Handbook recommendations.
View the pneumococcal disease chapter in the Australian Immunisation Handbook